![]() | This article is rated Stub-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
|
![]() | The
Wikimedia Foundation's
Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see
WP:PAID. For advice about reviewing paid contributions, see
WP:COIRESPONSE.
|
![]() | This edit request by an editor with a conflict of interest has now been answered. |
Hello! My name is Valentine, I'm an employee of Imbrium, the company developing sunobinop. I joined Wikipedia to put forth a more accurate, and in doing so, comprehensive description of sunobinop. I understand that because of my financial conflict I cannot make the changes to the article directly. I've prepared the infobox and text below that I think makes the article more accurate and up to date. Would someone here be willing to review and implement if it looks good? As I'm here, I welcome others to make any changes needed to meet Wikipedia's standards.
Extended content
| ||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sunobinop (developmental code names V117957; IMB-115) is an investigational drug under study. It is a novel, high affinity, high-potency, small molecule agonist of the nociceptin/orphanin-FQ peptide (NOP) receptor. Sunobinop has nanomolar affinity (Ki) and efficacy (EC50) at human recombinant NOP receptors. It has low binding affinity for mu, kappa and delta opioid receptors (Ki >1500 nM). It also has a high degree of functional selectivity for the NOP receptor as its EC50 against mu, delta and kappa receptors is between 500- and 5000-fold greater than for the NOP receptor. [1] Sunobinop was generally well tolerated in 3 studies involving 70 healthy subjects at doses that ranged from 0.6 to 30 mg. The most prominent adverse event was dose-dependent sedation/somnolence, which was more common at doses greater than 10 mg. In these studies, the majority of absorbed sunobinop was excreted unchanged via rapid renal elimination. [2] As of Feb 2024, it is under clinical investigation for the treatment of insomnia/alcohol use disorder, interstitial cystitis, and overactive bladder. [3] The safety and effectiveness of sunobinop has not been evaluated by the FDA. There is no guarantee that sunobinop will successfully complete development or gain FDA approval. [3] References
|
Thank you for taking a look, and drop me a line if you have any questions. ImbriumValentine ( talk) 19:13, 3 May 2024 (UTC)
![]() | This article is rated Stub-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
|
![]() | The
Wikimedia Foundation's
Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see
WP:PAID. For advice about reviewing paid contributions, see
WP:COIRESPONSE.
|
![]() | This edit request by an editor with a conflict of interest has now been answered. |
Hello! My name is Valentine, I'm an employee of Imbrium, the company developing sunobinop. I joined Wikipedia to put forth a more accurate, and in doing so, comprehensive description of sunobinop. I understand that because of my financial conflict I cannot make the changes to the article directly. I've prepared the infobox and text below that I think makes the article more accurate and up to date. Would someone here be willing to review and implement if it looks good? As I'm here, I welcome others to make any changes needed to meet Wikipedia's standards.
Extended content
| ||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sunobinop (developmental code names V117957; IMB-115) is an investigational drug under study. It is a novel, high affinity, high-potency, small molecule agonist of the nociceptin/orphanin-FQ peptide (NOP) receptor. Sunobinop has nanomolar affinity (Ki) and efficacy (EC50) at human recombinant NOP receptors. It has low binding affinity for mu, kappa and delta opioid receptors (Ki >1500 nM). It also has a high degree of functional selectivity for the NOP receptor as its EC50 against mu, delta and kappa receptors is between 500- and 5000-fold greater than for the NOP receptor. [1] Sunobinop was generally well tolerated in 3 studies involving 70 healthy subjects at doses that ranged from 0.6 to 30 mg. The most prominent adverse event was dose-dependent sedation/somnolence, which was more common at doses greater than 10 mg. In these studies, the majority of absorbed sunobinop was excreted unchanged via rapid renal elimination. [2] As of Feb 2024, it is under clinical investigation for the treatment of insomnia/alcohol use disorder, interstitial cystitis, and overactive bladder. [3] The safety and effectiveness of sunobinop has not been evaluated by the FDA. There is no guarantee that sunobinop will successfully complete development or gain FDA approval. [3] References
|
Thank you for taking a look, and drop me a line if you have any questions. ImbriumValentine ( talk) 19:13, 3 May 2024 (UTC)